UPK2 Human

UPK2 is synthesized as a major differentiation product of mammalian urothelium. It is involved in the formation of urothelial plaques, which are essential for the permeability barrier function of the bladder . The protein is characterized by its single-pass transmembrane domain and is expressed predominantly in the ureter . The recombinant form of UPK2 is often produced with an N-terminal His-tag for purification purposes .

Recombinant Human Uroplakin II is typically produced in E. coli and includes an N-terminal His-tag to facilitate purification. The recombinant protein corresponds to the amino acids 26-155 of the human UPK2 sequence . It is used in various research applications, including studies on bladder cancer and urothelial biology.

The UPK2 promoter has been identified and utilized in constructing urothelium-specific adenovirus variants for bladder cancer research . For instance, the CG8840 adenovirus variant, driven by the UPK2 promoter, has shown high specificity and efficacy in eliminating bladder tumors in combination with chemotherapy . This highlights the potential of UPK2 in developing targeted therapies for bladder cancer.

Recombinant UPK2 is typically stored in a buffer containing Tris-HCl, urea, and glycerol to maintain its stability. It is recommended to store the protein at 4°C for short-term use and at -20°C for long-term storage, avoiding freeze-thaw cycles to preserve its integrity .